Voyager Therapeutics, Inc. VYGR

Healthcare SIC 2836 - Biological Products, (No Diagnostic Substances) NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing derived Nasdaq

We are a biotechnology company whose mission is to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Our pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of our programs are derived from our TRACER™ (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which we have used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Some of our programs are wholly-owned, and some are advancing with licensees and collaborators, including Alexion, AstraZeneca Rare Disease, or Alexion; Novartis Pharma AG, or Novartis; Neurocrine Biosciences, Inc., or Neurocrine; and Transition Bio, Inc., or Transition Bio.

Last close 1.74 2026-10-23
Market cap $107.2M 2026-06-30 share count
52-week range 1.74 - 5.48

Valuation FY2025 figures against the last close

P/S2.7x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-2.04

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $40.4M$80.0M$250.0M$40.9M$37.4M$171.1M$104.4M$7.6M$10.1M$14.2M
R&D $134.7M$127.4M$92.2M$60.8M$73.8M$108.8M$119.7M$64.9M$62.3M$42.2M
SG&A $37.5M$35.9M$35.8M$31.0M$37.2M$35.0M$36.3M$33.8M$19.7M$13.3M
Total operating expenses $172.2M$163.3M$128.0M$91.7M$111.0M$143.7M$156.1M$98.7M$82.0M$55.5M
Operating income -$131.8M-$83.3M$122.0M-$50.8M-$73.6M$27.4M-$51.7M-$91.1M-$71.9M-$41.3M
Pre-tax income -$119.6M-$64.3M$133.7M-$46.4M-$71.2M$36.7M-$43.6M-$88.5M-$70.7M-$40.1M
Income tax $144.0K$665.0K$1.4M$16.0K———$180.0K—$52.0K
Net income -$119.7M-$65.0M$132.3M-$46.4M-$71.2M$36.7M-$43.6M-$88.3M-$70.7M-$40.2M
EPS, basic -2.04-1.133.08-1.21-1.890.99-1.21-2.75——
EPS, diluted -2.04-1.132.97-1.21-1.890.98-1.21-2.75-2.64-1.59
Shares, diluted (wtd. avg.) 58.7M57.7M44.6M38.4M37.7M37.3M35.9M32.1M——

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $65.3M$71.4M$70.4M$100.5M$119.2M$106.2M$86.8M$47.6M$32.3M$37.4M
Short-term investments $131.1M$195.3M$162.1M$19.9M$15.1M$76.7M$195.5M$108.9M$137.5M$137.8M
Receivables $1.8M$1.5M$80.2M———————
Total current assets $202.7M$276.8M$319.7M$124.5M$136.7M$197.8M$304.7M$162.5M$171.8M$178.8M
Property, plant and equipment $13.1M$14.3M$16.5M$17.9M$21.9M$25.4M$18.0M$12.8M$10.3M$7.9M
Total assets $252.3M$393.1M$351.3M$159.4M$193.9M$261.6M$354.8M$177.0M$184.5M$189.6M
Accounts payable $5.0M$4.0M$1.6M$2.6M$574.0K$634.0K$4.1M$1.0M$1.0M$550.0K
Total current liabilities $26.5M$49.8M$64.5M$72.6M$51.0M$26.8M$76.0M$31.7M$15.9M$13.8M
Total liabilities $56.2M$93.3M$115.0M$100.3M$98.8M$107.3M$255.2M$130.6M$50.4M$53.6M
Retained earnings -$445.9M-$326.2M-$261.2M-$393.5M-$347.1M-$275.9M-$312.6M-$269.1M-$160.7M-$90.0M
Total equity $196.1M$299.8M$236.3M$59.0M$95.1M$154.3M$99.5M$46.4M$134.1M$135.9M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$132.5M-$15.3M$77.9M-$12.5M-$53.5M-$96.7M$48.7M-$15.9M-$61.4M-$42.5M
Depreciation and amortisation $4.1M$4.7M$4.4M$6.2M$5.2M$3.8M$2.8M$2.1M$1.6M$612.0K
Stock-based compensation $14.8M$14.8M$11.2M$9.3M$11.3M$14.9M$15.6M$15.7M$9.2M$6.3M
Capital expenditure $2.6M$3.5M$3.3M$2.5M$1.6M$12.1M$7.7M$4.3M$4.0M$5.0M
Investing cash flow $125.4M-$94.9M-$141.6M-$7.3M$65.9M$113.0M-$90.5M$26.5M-$3.7M$47.7M
Financing cash flow $816.0K$114.0M$33.6M$1.1M$612.0K$3.2M$81.0M$4.7M$59.9M$514.0K

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-050297.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M -100M 0 100M 200M 300M Revenue, FY2016: 14.2M Net income, FY2016: -40.2M Revenue, FY2017: 10.1M Net income, FY2017: -70.7M Revenue, FY2018: 7.6M Net income, FY2018: -88.3M Revenue, FY2019: 104.4M Net income, FY2019: -43.6M Revenue, FY2020: 171.1M Net income, FY2020: 36.7M Revenue, FY2021: 37.4M Net income, FY2021: -71.2M Revenue, FY2022: 40.9M Net income, FY2022: -46.4M Revenue, FY2023: 250M Net income, FY2023: 132.3M Revenue, FY2024: 80M Net income, FY2024: -65M Revenue, FY2025: 40.4M Net income, FY2025: -119.7M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $14.2M $10.1M $7.6M $104.4M $171.1M $37.4M $40.9M $250.0M $80.0M $40.4M
Gross profit — — — — — — — — — —
Net income -$40.2M -$70.7M -$88.3M -$43.6M $36.7M -$71.2M -$46.4M $132.3M -$65.0M -$119.7M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Other event Item 8.01
  • Results announced Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2836

TickerCompanyMarket capP/ERevenue growth
AMGN AMGEN INC $237.48B 30.9x 10.0%
GILD GILEAD SCIENCES, INC. $193.48B 23.0x 2.4%
MRNA Moderna, Inc. $79.89B — -39.9%
RVMD Revolution Medicines, Inc. $40.08B — —
BIIB BIOGEN INC. $37.01B 28.5x 2.2%
EXEL EXELIXIS, INC. $15.99B 23.2x 7.0%
NBIX NEUROCRINE BIOSCIENCES INC $14.51B 30.6x 21.4%
HALO HALOZYME THERAPEUTICS, INC. $14.26B 49.1x 37.6%